{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:48:44Z","timestamp":1787662124891,"version":"build-2736575974"},"reference-count":114,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jaad.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jaad.2017.06.044","type":"journal-article","created":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T16:16:44Z","timestamp":1505405804000},"page":"902-910.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"77","author":[{"given":"Julia","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswanath R.","family":"Belum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2017.06.044_bib1","first-page":"393","article-title":"Advances in the understanding and treatment of colorectal cancer","volume":"12","author":"Soreide","year":"2011","journal-title":"Discov Med"},{"key":"10.1016\/j.jaad.2017.06.044_bib2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3816\/CLC.2009.n.004","article-title":"Toxicity of targeted therapy in non-small-cell lung cancer management","volume":"10","author":"Ricciardi","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jaad.2017.06.044_bib3","first-page":"15","article-title":"Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers","volume":"20","author":"Vokes","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jaad.2017.06.044_bib4","first-page":"505","article-title":"The EGF receptor, an essential regulator of multiple epidermal functions","volume":"10","author":"Jost","year":"2000","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bib5","first-page":"149","article-title":"Dermatologic toxicities of targeted anticancer therapies","volume":"8","author":"Balagula","year":"2010","journal-title":"J Support Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bib6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00520-012-1623-4","article-title":"The development of a functional assessment of cancer therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18)","volume":"21","author":"Wagner","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2017.06.044_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","article-title":"Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic","volume":"14","author":"Rosen","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bib8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","article-title":"Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results","volume":"72","author":"Boone","year":"2007","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.jaad.2017.06.044_bib9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaad.2013.06.038","article-title":"Pruritus in patients\u00a0treated with targeted cancer therapies: systematic review and meta-analysis","volume":"69","author":"Ensslin","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bib10","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jaad.2014.12.010","article-title":"Incidence and risk of xerosis with targeted anticancer therapies","volume":"72","author":"Valentine","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bib11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s10147-007-0746-y","article-title":"Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202)","volume":"13","author":"Nishida","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na\u00efve patients with advanced melanoma","volume":"29","author":"Hersh","year":"2011","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1016\/j.jaad.2017.06.044_bib13","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1210\/jc.2013-3713","article-title":"A multicenter phase II trial of pazopanib in metastatic and progress medullary thyroid carcinoma: MC057H","volume":"99","author":"Bible","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2017.06.044_bib14","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/jc.2012-1520","article-title":"A multiinstitutional phase II trial of pazopanib monotherapy in advanced anaplastic thyroid cancer","volume":"97","author":"Bible","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaad.2017.06.044_bib15","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2008.18.2717","article-title":"Phase II trial of sorafenib in metastatic thyroid cancer","volume":"27","author":"Kloos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bib16","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.breast.2013.07.037","article-title":"Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer","volume":"22","author":"Curigliano","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.jaad.2017.06.044_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.lungcan.2012.09.019","article-title":"A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer","volume":"79","author":"Han","year":"2013","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.jaad.2017.06.044_bib18","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/annonc\/mdr614","article-title":"A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors","volume":"23","author":"Strosberg","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11060-012-0988-z","article-title":"Continuous daily sunitinib for recurrent glioblastoma","volume":"111","author":"Kreisl","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jaad.2017.06.044_bib20","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdr522","article-title":"A phase II study of sunitinib in recurrent and\/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC","volume":"23","author":"Chau","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bib21","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/cncr.26440","article-title":"Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma","volume":"118","author":"Barrios","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2017.06.044_bib22","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s10637-010-9438-y","article-title":"Phase II study of sunitinib as second-line treatment for advanced gastric cancer","volume":"29","author":"Bang","year":"2011","journal-title":"Invest New Drugs"},{"issue":"3","key":"10.1016\/j.jaad.2017.06.044_bib23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/jjco\/hyp146","article-title":"A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into treatment, efficacy, and safety","volume":"40","author":"Uemura","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bib24","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1200\/JCO.2008.20.5476","article-title":"Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bib25","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S1470-2045(09)70171-8","article-title":"Safety and efficacy of suntinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study","volume":"10","author":"Faivre","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bib26","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bib27","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","article-title":"Phase II study of sunitinib malate, on oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"26","author":"Burstein","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bib28","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1200\/JCO.2007.13.9303","article-title":"Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer","volume":"26","author":"Socinski","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bib29","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1200\/JCO.2007.12.8637","article-title":"Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy","volume":"25","author":"Saltz","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2017.06.044_bib30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/neuonc\/not161","article-title":"A single-arm phase II Austrian\/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)","volume":"16","author":"Hutterer","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bib31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00280-009-1070-1","article-title":"A phase II study of sunitinib in patients with recurrent and\/or metastatic non-nasopharyngeal head and neck cancer","volume":"65","author":"Fountzilas","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"22","key":"10.1016\/j.jaad.2017.06.044_bib32","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2009.26.9571","article-title":"Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2017.06.044_bib33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1530\/EJE-11-0129","article-title":"Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population","volume":"165","author":"Ahmed","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"19","key":"10.1016\/j.jaad.2017.06.044_bib34","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1200\/JCO.2008.20.9890","article-title":"Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas","volume":"27","author":"George","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jaad.2017.06.044_bib35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.jaad.2017.06.044_bib36","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2017.06.044_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2017.06.044_bib38","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.06.044_bib39","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.06.044_bib40","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bib41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.jaad.2017.06.044_bib42","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2017.06.044_bib43","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000366227","article-title":"An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma","volume":"87","author":"Sternberg","year":"2014","journal-title":"Oncology"},{"issue":"9829","key":"10.1016\/j.jaad.2017.06.044_bib44","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jaad.2017.06.044_bib45","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study","volume":"32","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2017.06.044_bib46","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.06.044_bib47","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.seminoncol.2012.01.009","article-title":"Advances in the management of cutaneous toxicities of targeted therapies","volume":"39","author":"Robert","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bib48","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/cncr.11812","article-title":"Imatinib mesylate causes hypopigmentation in the skin","volume":"98","author":"Tsao","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2017.06.044_bib49","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2133.2006.07359.x","article-title":"Imatinib mesilate inihibits melanogenesis in\u00a0vitro","volume":"155","author":"Cario-Andre","year":"2006","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.06.044_bib50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in\u00a0vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaad.2017.06.044_bib51","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2008.01.001","article-title":"Chemotherapeutic agents and the skin: an update","volume":"58","author":"Heidary","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bib52","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00520-008-0536-8","article-title":"Skin and oral lesions associated to imatinib mesylate therapy","volume":"17","author":"Basso","year":"2009","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2017.06.044_bib53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-3083.2008.02706.x","article-title":"Imatinib-associated hyperpigmentation, a side effect that should be recognized","volume":"23","author":"McPherson","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2017.06.044_bib54","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/jid.2011.67","article-title":"The genetic determination of skin pigmentation: KITLG and the KITLG\/c-Kit pathway as key players in the onset of human familial pigmentary diseases","volume":"131","author":"Picardo","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bib55","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1111\/j.1600-0749.1992.tb00559.x","article-title":"The molecular basis of human piebaldism","volume":"5","author":"Spritz","year":"1992","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.jaad.2017.06.044_bib56","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1001\/jama.293.6.730","article-title":"New insights and new therapies in vitiligo","volume":"293","author":"Grimes","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2017.06.044_bib57","first-page":"857519","article-title":"Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica (Cairo)"},{"issue":"21","key":"10.1016\/j.jaad.2017.06.044_bib58","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.jaad.2017.06.044_bib59","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1200\/jco.2010.28.15_suppl.8571","article-title":"Hair depigmentation as an indicator of a durable response to CTLA-4 therapy","volume":"28","author":"Pavlick","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2017.06.044_bib60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bib61","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS1","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1200\/JCO.2004.02.168","article-title":"Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer","volume":"22","author":"Chang","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jaad.2017.06.044_bibS2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D3472203P2","article-title":"Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST","volume":"14","author":"Alexandrescu","year":"2008","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2017.06.044_bibS3","first-page":"298","article-title":"Dermatological toxicity of imatinib mesylate","volume":"53","author":"Prasad","year":"2005","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.jaad.2017.06.044_bibS4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2515\/therapie\/2014018","article-title":"Facial\u00a0hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor","volume":"69","author":"Hamza","year":"2014","journal-title":"Therapie"},{"key":"10.1016\/j.jaad.2017.06.044_bibS5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/MPH.0b013e318033a76c","article-title":"Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia","volume":"29","author":"Singh","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4103\/0378-6323.182387","article-title":"Imatinib induced melasma-like pigmentation: report of five cases and review of literature","volume":"82","author":"Ghunawat","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"10.1016\/j.jaad.2017.06.044_bibS7","article-title":"Imatinib induced facial skin hyperpigmentation in a case of chronic myelogenous leukemia","volume":"12","author":"Valizadeh","year":"2011","journal-title":"Shiraz E-Medical J"},{"key":"10.1016\/j.jaad.2017.06.044_bibS8","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.jaad.2008.06.029","article-title":"Imatinib mesylate\u2013induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors","volume":"59","author":"Han","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2017.06.044_bibS10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5070\/D31910020020","article-title":"Gefitinib-associated vitiligo: report in a man with parotid squamous cell carcinoma and review of drug-induced hypopigmentation","volume":"19","author":"Jalalat","year":"2013","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2017.06.044_bibS11","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/cncr.11812","article-title":"Imatinib mesylate causes hypopigmentation in the skin","volume":"98","author":"Tsao","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2017.06.044_bibS12","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1200\/JCO.2002.20.3.869","article-title":"Depigmentation in a chronic myeloid leukemia patient treated with STI-471","volume":"20","author":"Raanani","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS13","first-page":"722","article-title":"Hypopigmentation in an African patient treated with imatinib mesylate: a case report","volume":"95","author":"Hasan","year":"2003","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.jaad.2017.06.044_bibS14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00043426-200403000-00016","article-title":"Hypopigmentation from imatinib mesylate (Gleevac)","volume":"26","author":"Grossman","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1525-1470.2006.00208.x","article-title":"Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colormetric assessment","volume":"23","author":"Brazzelli","year":"2006","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2133.2005.06813.x","article-title":"Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo?","volume":"153","author":"Legros","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS17","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2141.2005.05431.x","article-title":"Loss of skin pigment caused by imatinib therapy","volume":"129","author":"McPartlin","year":"2005","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.jaad.2017.06.044_bibS18","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/j.leukres.2008.12.023","article-title":"Vitiligo-like lesions in an adult patient treated with imatinib mesylate","volume":"33","author":"Cerchione","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaad.2017.06.044_bibS19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2340\/00015555-1289","article-title":"Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib","volume":"92","author":"Brazzelli","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/1346-8138.13150","article-title":"Reversible skin and hair depigmentation during chemotherapy with dasatinib for chronic myeloid leukemia","volume":"43","author":"Fujimi","year":"2016","journal-title":"J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2017.06.044_bibS21","first-page":"QD01","article-title":"Diffuse hypopigmentation followed by hyperpigmentation in an African American woman with hemangiopericytoma treated with dasatinib","volume":"8","author":"Boudadi","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.jaad.2017.06.044_bibS22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2340\/00015555-1897","article-title":"Immunotherapy-induced leukoderma from treatment of melanoma with IL-2: a case report and a review of the literature","volume":"95","author":"Gathings","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS23","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1200\/JCO.2009.26.4432","article-title":"Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib","volume":"28","author":"Sideras","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS24","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/archderm.144.11.1525","article-title":"Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition","volume":"144","author":"Hartmann","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS25","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jaad.2008.12.030","article-title":"Skin depigmentation induced by sunitinib treatment of renal cell carcinoma","volume":"61","author":"Al Enazi","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.06.044_bibS26","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/j.jaad.2013.01.012","article-title":"Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma","volume":"69","author":"Alonso-Castro","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS27","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.15354","article-title":"A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma","author":"Wolner","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS28","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1111\/ijd.12174","article-title":"Lichenoid drug eruption with hyperpigmentation caused by imatinib mesylate","volume":"53","author":"Kagimoto","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS29","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/j.jcms.2011.07.010","article-title":"Imatinib-associated hyperpigmentation of the palate in post-HSCT patient","volume":"40","author":"Resende","year":"2012","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.jaad.2017.06.044_bibS30","doi-asserted-by":"crossref","first-page":"532","DOI":"10.5021\/ad.2014.26.4.532","article-title":"Imatinib mesylate-induced hyperpigmentation of the nose and palate","volume":"26","author":"Song","year":"2014","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/SMJ.0b013e31802f01a9","article-title":"Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma","volume":"100","author":"Dasanu","year":"2007","journal-title":"South Med J"},{"key":"10.1016\/j.jaad.2017.06.044_bibS32","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archdermatol.2009.177","article-title":"Cutaneous pigmentation after photosensitivity induced by vandetanib therapy","volume":"145","author":"Kong","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/archdermatol.2011.30","article-title":"Successful laser treatment of vandetanib-associated cutaneous pigmentation","volume":"147","author":"Brooks","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS34","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/j.1365-4632.2011.05422.x","article-title":"Erlotinib-induced hair repigmentation","volume":"53","author":"Cheng","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS35","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1200\/JCO.2011.34.6858","article-title":"Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer","volume":"29","author":"Rodriguez","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jaad.2017.06.044_bibS36","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.leukres.2010.11.028","article-title":"Reversible hair depigmentation in a patient treated with imatinib","volume":"35","author":"Mariani","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaad.2017.06.044_bibS37","first-page":"395","article-title":"Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl\/Src family tyrosine kinase inhibitor","volume":"8","author":"Sun","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS38","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamadermatol.2013.75","article-title":"Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia","volume":"149","author":"Samimi","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS39","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/1346-8138.12654","article-title":"Reversible hair depigmentation in a Japanese female treated with pazopanib","volume":"41","author":"Kobayashi","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1684\/ejd.2014.2462","article-title":"Eruptive nevi and hair depigmentation related to regorafenib","volume":"25","author":"Sibaud","year":"2015","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS41","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1056\/NEJMicm1309906","article-title":"Sunitinib-associated hair depigmentation","volume":"370","author":"Brzezniak","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2017.06.044_bibS42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1179\/ACB.66.1.2062522","article-title":"Blue-black discoloration of the nails associated with gefitinib","volume":"66","author":"Huan","year":"2011","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.jaad.2017.06.044_bibS43","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1365-2230.2011.04196.x","article-title":"Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib","volume":"37","author":"Steele","year":"2012","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/0378-6323.19727","article-title":"Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia","volume":"72","author":"Prabhash","year":"2006","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-3083.2008.02706.x","article-title":"Imatinib-associated hyperpigmentation, a side effect that should be recognized","volume":"23","author":"Mcpherson","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2017.06.044_bibS46","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000338893","article-title":"Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor","volume":"224","author":"Peuvrel","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2017.06.044_bibS47","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/ajh.23589","article-title":"Imatinib-associated melanosis of the palate","volume":"89","author":"Roeker","year":"2014","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.jaad.2017.06.044_bibS48","first-page":"4","article-title":"Oral melanosis after tyrosine kinase inhibition with imatinib for chronic myelogenous leukemia: report of a case and review of the literature","volume":"17","author":"Wong","year":"2011","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2017.06.044_bibS49","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s12105-011-0325-4","article-title":"Mucosal pigmentation caused by imatinib: report of three cases","volume":"6","author":"Li","year":"2012","journal-title":"Head Neck Pathol"},{"issue":"8","key":"10.1016\/j.jaad.2017.06.044_bibS50","first-page":"24","article-title":"Diffuse pigmentation of the palate","volume":"100","author":"Lewis","year":"2009","journal-title":"J Okla Dent Assoc"},{"key":"10.1016\/j.jaad.2017.06.044_bibS51","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3109\/10428194.2012.702904","article-title":"Hyperpigmentation of the hard palate associated with imatinib therapy for chronic\u00a0myeloid leukemia with a genetic variation in the proto-oncogene c-KIT","volume":"54","author":"Khoo","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.jaad.2017.06.044_bibS52","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.tripleo.2010.11.006","article-title":"Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases","volume":"111","author":"Mattsson","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.jaad.2017.06.044_bibS53","first-page":"764","article-title":"Oral and maxillofacial pathology case of the month. Palatal melanosis associated with imatinib mesylate therapy","volume":"129","author":"Yu","year":"2012","journal-title":"Tex Dent J"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217319461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217319461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T15:11:05Z","timestamp":1750864265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217319461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":114,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0190962217319461"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.06.044","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.06.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}